T. Platelet activation in the presence of neutral protamine Hagedorn insulin: a new feature of antibodies against protamine/heparin complexes.
Introduction
Unfractionated heparins (UFHs) and low-molecularweight heparins (LMWHs) are the most widely used anticoagulants in in-hospital patients. Especially LMWHs are increasingly used for thrombosis prophylaxis in medical patients [1, 2] . A special indication for heparin is its use during cardiac surgery [3, 4] . Heparin can be neutralized at the end of surgery by protamine sulfate (PRT), leading to the formation of PRT/heparin complexes [3] . Recently, it has been demonstrated that PRT/heparin complexes induce immunoglobulin G (IgG) antibodies (Abs) in about 25-30% of patients after cardiac surgery [5] [6] [7] . An unexpected finding of these studies was that almost 10% of patients were pre-immunized (IgG Abs against PRT/ heparin complexes) before surgery with no association with pre-exposure to PRT during preceding cardiac surgery. In contrast, the co-morbidity of diabetes mellitus (28-54%) was a risk factor for the immunization against PRT/heparin complexes [5] [6] [7] . Patients suffering from diabetes mellitus may be treated with insulin to control glucose levels. In some preparations insulin is stabilized by PRT, neutral protamine Hagedorn (NPH) insulin, to delay the release of insulin into the circulation and to prolong duration of insulin action [8] [9] [10] .
In this study, we analyzed the interaction between NPH-insulin, anti-PRT/heparin-Abs and platelets (PLTs). We found that NPH-insulin binds to PLTs in a heparindependent way. Moreover, anti-PRT/heparin-Abs activated PLTs in the presence of NPH-insulin, which was enhanced by heparin. However, results from our preliminary study indicate no major impact of these Abs on the clinical outcome in medical patients receiving heparin, particularly on thromboembolic complications.
Materials and methods

Index patient
A 72-year-old diabetic man on insulin treatment (containing aspart PRT crystals) was readmitted with suspected septicemia to the University Hospital of Vienna after orchiectomy. The patient had mild hepatosplenomegaly and renal insufficiency, a history of arterial hypertension and diabetes, coronary heart disease (stent implantation) and amputation of one leg due to peripheral arterial disease, 1 year ago. Acute treatment included, among other medications, NPH-insulin, antibiotics and continuous intravenous UFH. Five days later, a drop in PLT counts from 117 9 10 9 /L to 72 9 10 9 /L was recorded and serological investigations for heparininduced thrombocytopenia (HIT) were initiated. The patient's sample was investigated using two commercially available assays, namely LFI-HIT (Milenia Biotec, Giessen, Germany) and Zymutest HIA IgG (Hyphen Biomed, Neuville sur Oise, France). Although the LFI-HIT test was negative, indicating the absence of Abs against platelet factor 4 (PF4)/heparin complexes, the Zymutest HIA IgG showed strong reactions in the absence as well as in the presence of PLT lysate. Anti-PRT/heparin-Abs were suspected (as the assay contains PRT for fixation of heparin to the microtiter plate). Anticoagulation was switched to argatroban (later to danaparoid). The PLT count rose after 2 days to 91 9 10 9 /L and was 134 9 10 9 /L another 5 days later. Using two in-house enzyme immunoassays (EIA), strong IgG binding to PRT/heparin complexes was observed, but not to PRT alone (optical density [OD], 1.33 and 0.28, respectively; cut-off, 0.5). Because NPH-insulin was the only documented source of PRT in our patient, we hypothesized that anti-PRT/heparin-Abs may be responsible for thrombocytopenia by activating PLTs in the presence of NPH-insulin and heparin. Indeed, patients' serum activated PLTs in the presence of NPH-insulin as assessed by P-selectin expression by flow cytometry (FC; mean fluorescence intensity [MFI], 101; control, 36). PLT activation was inhibited in the presence of high concentrations of heparin and by blocking the PLT FccIIa receptor using the monoclonal antibody (moAb) IV.3 (MFI, 37 and 28, respectively). The presence of PLTactivating Abs maximally reactive in vitro in the presence of both NPH-insulin and heparin was a plausible explanation for post-surgery thrombocytopenia. However, the key unresolved issue is the precise trigger of immunization and the timing of onset of Ab formation (previous PRT treatment or current NPH-insulin therapy).
Patients and sera
To assess the interaction between anti-PRT/heparin-Abs and NPH-insulin in vitro, patient samples containing anti-PRT/heparin-Abs available from recent studies were used [11] [12] [13] [14] .
The clinical relevance of PLT-activating Abs in medical patients was assessed using a previously described cohort [15] . In this open-label, active-controlled, multicenter study, 335 in-hospital medical patients received certoparin or UFH for thromboprophylaxis. Blood samples were collected for determination of PLT count on the day of initiation of heparin therapy (day 1), at day 6 AE 1 and on the first day after the end of the treatment (treatment period of 10 AE 2 days). Ab testing was performed for 332 patients on day 1 and day 10 AE 2. Thrombocytopenia was defined as a decline in the PLT count below 100 9 10 9 /L, or a decrease of > 50% in comparison to the baseline value (day 1), occurring during the treatment period. The primary endpoint was a composite of symptomatic or asymptomatic proximal or distal deep vein thrombosis, symptomatic pulmonary embolism or venous thromboembolism (VTE)-related death. Blood samples were aliquoted and stored at À80°C until use.
Binding of anti-PRT/heparin-Abs to NPH-insulin
Binding of anti-PRT/heparin-Abs to NPH-insulin was analyzed using two EIAs: (i) a standard EIA for detection of direct Ab-binding to immobilized NPH-insulin and (ii) a competitive EIA to determine competitive inhibition of Ab-binding to immobilized PRT/heparin complexes by NPH-insulin in the fluid phase.
Direct binding of anti-PRT/heparin-Abs to NPH-insulin was determined using an in-house EIA. NPH-insulin (1 lg mL À1 , Berlinsulin H Basal, Berlin-Chemie AG, Ab-binding was then tested using anti-human IgG. Buffer and native insulin were used as negative control. Ab-binding in the presence of buffer was defined as 100%. All patients' samples were analyzed in duplicates.
Binding of NPH-insulin to PLTs
PLTs were isolated from whole blood anticoagulated with citrate dextrose solution (solution A; ACD-A) as previously described [16] and resuspended in Tyrode-buffer. PLTs (1 9 10 7 ) were incubated with different concentrations of NPH-insulin (0-200 lg mL À1 , Berlinsulin H Basal; 10 min at 37°C), then a monoclonal murine antihuman insulin-FITC-Ab (clone 1G11, 1 : 100; Bioss Inc., Woburn, MA, USA) was added for 30 min at RT. PLTs were washed once using 2 mL wash-buffer (136.9 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO 3 , 4.2 mM NaH 2 PO 4 , 0.35% BSA, 0.1% glucose, pH 7.2; 650 9 g, 7 min, RT, without brake). Ab-binding was measured using FC (Cytomics FC 500, Beckman Coulter, Fullerton, CA, USA). Native insulin (0-200 lg mL À1 ; Actrapid) was used as control.
To study the impact of heparin on insulin binding, PLTs were incubated with insulin (native or NPH-insulin as mentioned above) in the presence of increasing concentrations of UFH (0-100 IU mL
À1
; Heparin-Natrium-25000-ratiopharm).
Binding of anti-PRT/heparin-Abs to PLTs in the presence of NPH-insulin
The ability of anti-PRT/heparin-Abs to bind PLTs in the presence of NPH-insulin was tested using FC. Washed PLTs (1 9 10 7 ) were incubated (30 min, 37°C) with patients' serum in the presence of: (i) suspension-buffer (DPBS-buffer/0.05% BSA), (ii) NPH-insulin (50 lg mL À1 ;
Berlinsulin H Basal) or (iii) NPH-insulin and UFH (0.1 IU mL
À1
; Heparin-Natrium-25000-ratiopharm). After incubation, PLTs were fixed using 2% paraformaldehyde (Morphisto, Frankfurt am Main, Germany) for 20 min at RT, washed twice with wash-buffer (2 mL DPBS/0.05% BSA; 650 9 g, 7 min, RT) and resuspended in 100 lL washing-buffer. Ab-binding was determined by FC using FITC-conjugated rabbit-anti-human IgG (diluted 1 : 20; Dako, Glostrup, Denmark).
Anti-PRT/heparin-mediated PLT activation
The ability of anti-PRT/heparin-Abs to induce PLT activation was investigated by the modified heparin-induced platelet-aggregation (mHIPA) assay as previously described [5] . In brief, serum was incubated with washed PLTs in the presence of: (i) buffer, (ii) PRT, (iii) heparin or (iv) PRT and heparin. PLT aggregation determined visually in at least two PLT suspensions in the presence of PRT or PRT and heparin, but not buffer or heparin alone, was considered positive.
Anti-PRT/heparin-induced PLT activation in the presence of NPH-insulin was assessed by P-selectin (CD62P) expression on the PLT surface using FC. Washed PLTs (1 9 10 7 ) were incubated (30 min, 37°C) with patients' serum (1 : 10 diluted) in the presence of: (i) suspensionbuffer, (ii) NPH-insulin (Berlinsulin H Basal), (iii) NPHinsulin and UFH (Heparin-Natrium-25000-ratiopharm) or (iv) NPH-insulin, UFH and moAb IV.3. Native insulin (Actrapid) served as negative control.
To analyze the impact of heparin on Ab-mediated PLT activation, different concentrations of NPH-insulin were investigated in the presence of different concentrations of UFH (Heparin-Natrium-25000-ratiopharm) or LMWH (Clivarin 1.750). After incubation, PLTs were fixed using 2% paraformaldehyde for 20 min at RT and washed twice with wash-buffer (2 mL DPBS/0.05% BSA; 650 9 g, 7 min, RT). The PLT pellet was then resuspended in 100 lL wash-buffer and tested using FC. PLTs were gated using a mouse-anti-human CD41-FITC labelled moAb (clone SZ22; diluted 1 : 20) and CD62P expression was determined using the monoclonal mouseanti-human CD62P-PE-Cy5-Ab (clone AK-4; diluted 1 : 20; BD Biosciences) (30 min, RT).
Statistical analyses
The statistical analysis was performed using GraphPad Prism, Version 5.0 (GraphPad, La Jolla, CA, USA). Non-parametric tests were used when data failed to follow a normal distribution as assessed by the D'Agostino and Pearson omnibus normality test. Group comparison was performed using the Wilcoxon rank-sum test and the Fisher exact test with categorical variables. In the case of a small number of experiments (< 10) the group comparison was performed using the t-test. All analyses were two-tailed and a P-value of < 0.05 was defined as statistically significant.
Results
Anti-PRT/heparin-Abs bind to NPH-insulin
When NPH-insulin was immobilized onto microtiter plates, sera from 56 healthy donors showed a mean OD of 0.181 AE 0.128 standard deviation (SD), resulting in a cut-off (mean + 2 9 SD) of ≥ 0.5. We then analyzed 90 selected sera obtained from medical and surgical patients who had been enrolled in previous studies [11] [12] [13] [14] , characterized for anti-PRT/heparin-Abs. None of the sera bound to PRT alone. In the PRT/heparin EIA, 10 sera tested negative (group I, median OD: 0.033, range 0.015-0.330, 95% confidence interval [CI] 0.000-0.136) and 56 sera tested positive (group II, median OD: 0.728, range 0.505-1.860, 95% CI 0.726-0.867) and 24 sera tested positive in the EIA as well as in the mHIPA assay (group III, median OD: 0.680, range 0.500-1.175, 95% CI 0.651-0.840) (Fig. 1A) .
In the NPH-insulin EIA, a total of 22 of the 56 sera tested positive; among them only one sample also tested positive for anti-insulin-Abs (Fig. 1, grey symbol) . Of the remaining 21 sera, 12 (21.4%) belonged to group II and 9 (37.5%) to group III. No significant difference in binding was observed between non-PLT-activating (group II) and PLT-activating anti-PRT/heparin-Abs (group III) (median OD: 0.710, range 0.500-1.355 vs. 0.805, range 0.515-1.765, respectively; 95% CI 0.626-0.977 vs. 95% CI 0.614-1.207, respectively; P = 0.458). Of the group I sera without detectable Abs against PRT/heparin complexes, one serum bound to NPH-insulin (OD: 0.580).
Four representative sera containing anti-PRT/heparinAbs with binding to NPH-insulin were tested in the competitive EIA. Anti-PRT/heparin-Ab binding was significantly reduced by NPH-insulin ( 95% CI 3.6-3.8, respectively; P < 0.001; Figure S1 ). Binding of NPH-insulin to PLTs was charge-dependent as heparin inhibited binding of NPH-insulin to PLTs at concentrations ≥ 1 IU mL À1 (compared with NPH-insulin alone, P = 0.006; Figure S1 ). We next investigated the ability of anti-PRT/heparinAbs to bind to PLTs in the presence of NPH-insulin. anti-protamine (PRT)/heparin antibodies to bind platelets (PLTs) in the presence of neutral protamine Hagedorn (NPH) insulin and its impact on PLT activation was examined using flow cytometry. PLT activation was determined by measuring P-selectin (CD62P) expression. Lines indicate median of mean fluorescence intensity (MFI) and range; ns, not significant. P-values of < 0.05 were assumed to represent statistical significance. (A) Antibody binding to platelets. PLTs were incubated with patients' sera (n = 3) containing anti-PRT/heparin immunoglobulin G (IgG) antibodies in the presence of: (i) buffer (white bar), (ii) NPH-insulin (first dark grey bar) or (iii) NPH-insulin and unfractionated heparin (UFH; rear dark grey bars). Anti-PRT/heparin IgG antibodies bind to PLTs in the presence of NPH-insulin. (B) Antibody-mediated platelet activation. PLTs (n = 2) were incubated with sera containing anti-PRT/heparin IgG antibodies (n = 6) in the presence of (i) native insulin (light grey bars) or (ii) NPH-insulin (dark grey bars), in the presence of buffer or UFH. The FcɣIIa receptor-blocking monoclonal antibody (moAb) IV.3 was used as an inhibition step. No PLT activation was observed after incubation of control sera in the presence of NPH-insulin, PRT or PRT/heparin complexes (data not shown).
The minimum concentration of NPH-insulin required for the Ab-mediated PLT activation was determined using two sera containing strong PLT-activating Abs. Sera were incubated with PLTs from two different donors together with a mixture of NPH-insulin and heparin dilutions (LMWH or UFH) starting from the optimal concentration of 50 lg mL À1 NPH-insulin and 0. Fig. 3A) . The ratio between heparin and NPH-insulin was critical for Ab-mediated PLT activation; beyond the optimal concentration, higher concentrations of UFH or LMWH inhibited PLT activation (Fig. 3B) .
To mimic clinical situations of patients receiving heparin for VTE prophylaxis, Ab-mediated PLT activation was investigated in the presence of low concentrations of heparin (0.05 and 0.1 IU mL À1 ). A statistically significant increase in P-selectin expression was observed in the presence of at least 12.5 lg mL , Figure S2 ).
The incidence and clinical relevance of Abs against PRT/ heparin complexes and NPH-insulin in medical inpatients
Samples from a cohort of 332 medical inpatients were investigated for anti-PRT/heparin-Abs using the in-house PRT/heparin IgG EIA and for PLT activation using the mHIPA assay. Twenty-one out of 332 (6.3%) patients tested positive for anti-PRT/heparin IgG in the EIA at any time-point (median OD: 0.650, range 0.515-1.930, 95% CI 0.668-0.951). At study entry (day 1), 14 patients tested already positive for anti-PRT/heparin-Abs. A further seven patients seroconverted within 10 days. Sera from five out of 21 (23.8%) patients induced PLT activation in the mHIPA assay in the presence of PRT and heparin, but not in the presence of heparin alone (all patients tested positive at study entry).
Using an NPH-insulin EIA, sera from 36 out of 332 (10.8%) patients tested positive for IgG Abs (median OD: 0.690, range 0.500-1.545, 95% CI 0.656-0.840); out of them, 27 tested positive at study entry. Of those, nine tested negative for anti-NPH-insulin-Abs after 1 week and seven patients seroconverted within 1 week. Abs against native insulin were detected in only three (8.3%) sera using an anti-insulin EIA (median OD: 1.380, range 1. 270-1.480, 95% CI 1.116-1.638) . Eleven of the 36 (30.6%) sera containing Abs against NPH-insulin induced slight PLT activation in the presence of NPH-insulin (50 lg mL À1 ) (CD62P expression, median MFI: 20.5, range 12.7-59.3 vs. buffer: 13.3, range 7.5-27.0; 95% CI 15.0-37.6 vs. 95% CI 11.1-15.2, respectively; P < 0.001).
PLT activation was strongly enhanced by the addition of UFH (0.1 IU mL À1 ) (median MFI: 87.5, range 42.1-858.0, 95% CI 67.6-476.1; compared with NPH-insulin alone, P < 0.001). Interestingly, four sera with no detectable IgG Abs against PRT or PRT/heparin complexes induced PLT activation in the presence of NPH-insulin compared with buffer (median MFI: 24.4, range 15.9-32.5, 95% CI 11.7-36.8 vs. 16.4, range 10.7-21.8, 95% CI 6.3-26.3; P = 0.007). This activation was strongly enhanced by heparin (median MFI: 70.0, range 51.6-137.2, 95% CI 19.6-144.7; compared with NPH-insulin alone, P = 0.038).
The clinical impact of anti-PRT/heparin-Abs in medical inpatients
In the prospective study, five thromboembolic complications in total were observed (1.5%) and three (0.9%) major bleedings. Neither thromboembolic complication nor major bleeding was documented for patients who tested positive for anti-PRT/heparin-Abs (n = 21) or anti-NPH-insulin-Abs (n = 36). Nineteen patients died during the study period; all but one of them tested negative for anti-PRT/heparin-Abs as well as anti-NPH-insulin-Abs in an EIA.
Discussion
In this study, we provide further insights into the interaction between anti-PRT/heparin-Abs and PLTs. Our data demonstrate the ability of heparin-dependent anti-PRTAbs to bind to PRT-coupled NPH-insulin. The binding of anti-PRT/heparin-Abs to NPH-insulin on the PLT surface resulted in PLT activation via FccIIa receptors in a heparin-dependent manner. Although these biological features suggested clinical relevance, we observed no major impact of these Abs on the clinical outcome in medical patients receiving heparin, particularly on thromboembolic complications.
We clearly demonstrate that the interaction of anti-PRT/heparin-Abs with NPH-insulin is caused by the PRT part of NPH-insulin, as only one out of 21 sera reacting with NPH-insulin contained Abs against human insulin (Fig. 1A, grey symbol) . Most sera contained Abs that bound to PRT only in the presence of heparin (heparindependent), but a subset of Abs bound strongly to NPHinsulin even in the absence of heparin and no significant increase in Ab-binding was observed after addition of heparin (data not shown). Interestingly, these Abs did not bind to PRT alone, indicating that PRT in NPH-insulin has a different conformation than native PRT. At neutral pH, insulin is negatively charged (isoelectric pH of 5.4). A neutral pH value is achieved in the suspension by use of phosphate-buffer and zinc. One explanation for our observation could be that PRT changed its structure upon binding to negatively charged insulin in a similar way to that seen in PRT/heparin complexes (5).
NPH-insulin, but not native human insulin, bound to washed PLTs. In addition, binding of NPH-insulin to PLTs was inhibited by high concentrations of heparin ( Figure S1 ), indicating charge-dependence and suggesting that NPH-insulin binds via PRT to the PLT surface. It is likely that this binding occurs via glycosaminoglycans (GAG) on the PLT surface given the charge similarities between PRT and the chemokine PF4, but this needs to be proven by further experiments. Similar to PF4-binding, binding of anti-PRT/heparin-Abs to NPH-insulin-coated PLTs was significantly increased by heparin at low concentrations ( Fig. 2A) . Taken together, PRT mediates binding of NPH-insulin to PLTs, and heparin enhances the binding of anti-PRT/heparin-Abs, presumably by modifying the structure of PRT or by creating larger PRT complexes, or a composite of both.
Recently, thromboembolic complications have been observed in diabetic patients who have been treated with insulin and heparin [5, 17, 18] . These complications occurred in the early post-cardiac surgery period as well as in medical patients [18] . We hypothesized that PLT activation by anti-PRT/heparin-Abs in the presence of NPH-insulin may contribute to these complications. In our previous studies, anti-PRT/heparin-Ab-mediated PLT activation was investigated using the mHIPA assay [5] . In the mHIPA test, PLT activation is determined visually by the formation of PLT aggregates shifting the suspension from turbidity to transparency. NPH-insulin is a turbid crystalline solution, making visual determination of aggregate formation in the presence of NPH-insulin very challenging. Thus, we used FC to determine P-selectin expression as a marker for PLT activation and found that a subgroup of anti-PRT/heparin-Abs is able to activate PLTs in the presence of NPH-insulin via crosslinking PLT FccIIa receptors (Fig. 2B) . PLT activation was ), NPH-insulin concentrations above 25 lg mL À1 were required for induction of PLT activation by anti-PRT/heparin-Abs ( Figure S2B ). Using radiolabeled NPH-insulin, plasma concentrations between 10 and 15 lU mL À1 (corresponding to 0.35-0.52 lg mL À1 ) have been observed 4 hours after subcutaneous injection of NPH-insulin in newly diagnosed insulin-dependent diabetic patients [19] . Whether the concentrations of NPH-insulin required for PLT activation by anti-PRT/heparin-Abs in vitro are equivalent to the concentration of NPH-insulin required for PLT activation in vivo is currently unresolved. In addition, approximately 30-80% of systemic insulin is metabolized, particularly in the kidney [20] [21] [22] [23] . In the absence of pharmacokinetic studies for the various types of insulin in patients with different degrees of renal insufficiency, it is currently very difficult to assess the risk of NPH-insulin accumulation and subsequent Ab-mediated PLT activation in this patient population. In view of the data from our in vitro studies it is an interesting hypothesis that the increased risk of microand microvascular thrombosis, observed in diabetic patients treated with NPH-insulin [24] , may in part be related to immune-mediated PLT activation by Abs against NPH-insulin. Although the serological and functional properties of these Abs suggested considerable pathogenic effects, the lack of thromboembolic complications in the five individuals with PLT-activating anti-PRT/heparin-Abs in our cohort study indicates that the breakthrough of thrombosis is probably limited to only a subgroup of patients, as it is well known in patients with anti-PF4/heparin-Abs [25] . However, our clinical study has several limitations and should be considered as preliminary information indicating that anti-PRT/heparin-Abs are probably not highly prothrombotic if only NPH-insulin and heparin in prophylactic doses are given. As this was a post-hoc analysis, not preplanned in the study protocol, we did not have sufficient information on whether and how many diabetic patients received NPH-or native insulin. Second, changes in the PLT count < 50%, reaching a nadir of > 100 000 lL À1 , were not documented as an adverse reaction and we may have missed minor effects of these Abs on the PLT count. Third, these medical patients did not receive PRT intravenously for neutralization of heparin. Thus, no final conclusion can be drawn on the effect of anti-NPH-insulin-Abs or anti-PRT/heparinAbs on the risk of thromboembolic complications.
Taken together, our data demonstrate the ability of anti-PRT/heparin-Abs to activate PLTs in the presence of NPH-insulin in a heparin-dependent manner. Although these biological properties indicate a potential risk of concomitant treatment of diabetic patients with NPH-insulin and heparin, data from our preliminary study make a high rate of clinical breakthrough unlikely in medical patients receiving NPH-insulin and LMWH thrombosis prophylaxis at the same time. (UFH) in the presence of: (i) buffer (white bars), (ii) native insulin (light grey bars) or (iii) neutral protamine Hagedorn (NPH) insulin (dark grey bars). Data are presented as median of mean fluorescence intensity (MFI) and range. P-values of < 0.05 were assumed to represent statistical significance. Fig. S2 . Antibody-mediated platelet activation in the presence of neutral protamine Hagedorn insulin and heparin at therapeutic concentrations. Platelet (PLT)-activating antibodies were incubated with PLTs (n = 3) in the presence of different concentrations of neutral protamine Hagedorn (NPH) insulin and therapeutic concentrations of heparin (0.5 IU mL À1 unfractionated heparin [UFH] or low-molecular-weight heparin [LMWH]). Antibodymediated PLT activation was determined by measuring P-selectin (CD62P) expression. Data are presented as median of mean fluorescence intensity (MFI) and range.
